Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Number 139, Renmin Road, Changsha, 410011, Hunan, People's Republic of China,
Clin Transl Oncol. 2013 Oct;15(10):818-24. doi: 10.1007/s12094-013-1010-8. Epub 2013 Mar 9.
An increasing number of studies have shown that PUMA and C-myb signaling pathways are involved in various human cancers including colon carcinomas. However, few studies have examined gallbladder cancer specimens, and little is known about the clinical and pathological significance signaling changes may have in gallbladder adenocarcinoma. This study has investigated the expression of PUMA and C-myb in benign and malignant lesions of gallbladder and its pathological significance.
Tissue specimens from 108 gallbladder adenocarcinoma patients, 46 adjacent tissues, 15 cases of adenomatous polyps, and 35 surgical specimens from chronic cholecystitis patients were routinely paraffin embedded and sectioned. PUMA and C-myb expressions were detected with EnVision immunohistochemistry.
Positive rates of PUMA and C-myb are significantly higher in gallbladder adenocarcinoma tissues than that in the other three (P < 0.01). Gallbladder epithelial cells in PUMA and/or C-myb positive benign cases manifest moderate to severe atypical dysplasia. Positive rates of PUMA and C-myb in well-differentiated tumors with maximum diameter of <2 cm and with no lymph node metastasis and invasion of the surrounding tissues are significantly lower than that in those poorly differentiated cases with maximum diameter of ≥ 2 cm, lymph node metastasis, and invasion of the surrounding tissues (P < 0.05 or P < 0.01). The postoperative survival of patients whose tumor specimens are positive for PUMA and C-myb is significantly shorter than that of those who are negative for both markers (P < 0.05 or P < 0.01).
Our results have demonstrated that PUMA and C-myb positive gallbladder tumors progress rapidly, are prone to metastasis, possess strong invasive ability, and have poor prognosis.
越来越多的研究表明,PUMA 和 C-myb 信号通路参与了包括结肠癌在内的多种人类癌症。然而,很少有研究检查胆囊癌标本,并且对胆囊腺癌中信号变化的临床和病理意义知之甚少。本研究调查了 PUMA 和 C-myb 在胆囊良恶性病变中的表达及其病理意义。
常规石蜡包埋和切片,检测 108 例胆囊腺癌患者、46 例癌旁组织、15 例腺瘤性息肉和 35 例慢性胆囊炎患者的组织标本。采用 EnVision 免疫组化法检测 PUMA 和 C-myb 的表达。
胆囊腺癌组织中 PUMA 和 C-myb 的阳性率明显高于其他三种组织(P<0.01)。在 PUMA 和/或 C-myb 阳性的良性病例中,胆囊上皮细胞表现为中重度异型增生。最大直径<2cm、无淋巴结转移和周围组织浸润的高分化肿瘤中,PUMA 和 C-myb 的阳性率明显低于最大直径≥2cm、有淋巴结转移和周围组织浸润的低分化肿瘤(P<0.05 或 P<0.01)。肿瘤标本中同时表达 PUMA 和 C-myb 的患者术后生存时间明显短于均为阴性的患者(P<0.05 或 P<0.01)。
我们的研究结果表明,PUMA 和 C-myb 阳性的胆囊肿瘤进展迅速,易发生转移,具有较强的侵袭能力,预后不良。